Abstract The Food and Drug Administration (FDA) has approved vaccines designed by GSK, copyright and Moderna to protect high-risk populations against respiratory syncytial virus (RSV).These vaccines employ the pre-fusion F (pre-F) protein as the immunogen.In this study, we explored an mRNA vaccine based on a modified pre-F protein called LC2DM-lipid nanoparticle (LC2DM-LNP).This vaccine features a truncated version of the pre-F protein that is anchored to the cell membrane.
Our experiments in young and old female mice revealed that the LC2DM-LNP coastal clouds vanilla custard vaccine elicited robust neutralizing antibody titers.Moreover, LC2DM-LNP prompted a Th1-skewed T-cell immune response in female rodent models.Female ubahdank ipa cotton rats immunized with LC2DM-LNP demonstrated strong immunity to RSV, without signs of vaccine-enhanced respiratory disease (VERD), even in cases of breakthrough infection.Importantly, when administered to pregnant female cotton rats, LC2DM-LNP ensured the transfer of pre-F-specific antibodies to the offspring and provided protection against RSV without increasing lung inflammation.
Our findings suggest that LC2DM-LNP could serve as an alternative RSV vaccine candidate for high-risk groups.